Unknown

Dataset Information

0

Innovative agents in multiple myeloma.


ABSTRACT: Multiple myeloma (MM) remains an incurable cancer of the bone marrow plasma cells. However, the overall survival of patients with MM has increased dramatically within the past decade. This is due, in part, to newer agents such as immunomodulatory drugs (lenalidomide, thalidomide, and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, MLN9708). These and several other new classes of drugs have arisen from an improved understanding of the complex environment in which genetic changes occur. Improved understanding of genetic events will enable clinicians to better stratify risk before and during therapy, tailor treatment, and test the value of personalized interventions. The ultimate goal in this incurable disease setting is to reduce the impact of cancer- or chemotherapy-related side effects. Nurses and advanced practitioners are integral to the treatment team. Thus, each should be aware of changes to the current drug landscape. Targeted drugs with sophisticated mechanisms of action are currently under investigation. Patients gain access to newer drugs within the context of clinical trials. Awareness of such trials will help accrual and determine if therapeutic benefit exists. In this article, we will describe new agents with unique and targeted mechanisms of action that have activity in patients with relapsed and/or refractory multiple myeloma.

SUBMITTER: Faiman B 

PROVIDER: S-EPMC4114494 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Innovative agents in multiple myeloma.

Faiman Beth B   Richards Tiffany T  

Journal of the advanced practitioner in oncology 20140501 3


Multiple myeloma (MM) remains an incurable cancer of the bone marrow plasma cells. However, the overall survival of patients with MM has increased dramatically within the past decade. This is due, in part, to newer agents such as immunomodulatory drugs (lenalidomide, thalidomide, and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, MLN9708). These and several other new classes of drugs have arisen from an improved understanding of the complex environment in which genetic changes  ...[more]

Similar Datasets

| S-EPMC6589825 | biostudies-literature
| S-EPMC7654052 | biostudies-literature
| S-EPMC3234318 | biostudies-literature
| S-EPMC5348443 | biostudies-literature
| S-EPMC8477647 | biostudies-literature
| S-EPMC3228121 | biostudies-other
| S-EPMC4158738 | biostudies-literature
| S-EPMC7922387 | biostudies-literature
| S-EPMC9820921 | biostudies-literature
| PRJNA515992 | ENA